536 related articles for article (PubMed ID: 32486934)
1. Rituximab use as induction therapy for lupus nephritis: a systematic review.
Stolyar L; Lahita RG; Panush RS
Lupus; 2020 Jul; 29(8):892-912. PubMed ID: 32486934
[TBL] [Abstract][Full Text] [Related]
2. Efficacy and safety of rituximab in comparison with common induction therapies in pediatric active lupus nephritis.
Basu B; Roy B; Babu BG
Pediatr Nephrol; 2017 Jun; 32(6):1013-1021. PubMed ID: 28191596
[TBL] [Abstract][Full Text] [Related]
3. Rituximab vs mycophenolate and vs cyclophosphamide pulses for induction therapy of active lupus nephritis: a clinical observational study.
Moroni G; Raffiotta F; Trezzi B; Giglio E; Mezzina N; Del Papa N; Meroni P; Messa P; Sinico AR
Rheumatology (Oxford); 2014 Sep; 53(9):1570-7. PubMed ID: 24505125
[TBL] [Abstract][Full Text] [Related]
4. Differences in rituximab use between pediatric rheumatologists and nephrologists for the treatment of refractory lupus nephritis and renal flare in childhood-onset SLE.
Gilbert M; Goilav B; Hsu JJ; Nietert PJ; Meidan E; Chua A; Ardoin SP; Wenderfer SE; von Scheven E; Ruth NM;
Pediatr Rheumatol Online J; 2021 Aug; 19(1):137. PubMed ID: 34461932
[TBL] [Abstract][Full Text] [Related]
5. Long-term outcomes of lupus nephritis treated with regimens based on cyclophosphamide and mycophenolate mofetil.
Prasad N; Kurian J; Agarwal V; Bhadauria D; Behera M; Yacha M; Kushwaha R; Agrawal V; Jain M; Gupta A
Lupus; 2020 Jul; 29(8):845-853. PubMed ID: 32437258
[TBL] [Abstract][Full Text] [Related]
6. Pilot study comparing the childhood arthritis and rheumatology research alliance consensus treatment plans for induction therapy of juvenile proliferative lupus nephritis.
Cooper JC; Rouster-Stevens K; Wright TB; Hsu JJ; Klein-Gitelman MS; Ardoin SP; Schanberg LE; Brunner HI; Eberhard BA; Wagner-Weiner L; Mehta J; Haines K; McCurdy DK; Phillips TA; Huang Z; von Scheven E;
Pediatr Rheumatol Online J; 2018 Oct; 16(1):65. PubMed ID: 30348175
[TBL] [Abstract][Full Text] [Related]
7. Combination therapy of rituximab and mycophenolate mofetil in childhood lupus nephritis.
Hogan J; Godron A; Baudouin V; Kwon T; Harambat J; Deschênes G; Niel O
Pediatr Nephrol; 2018 Jan; 33(1):111-116. PubMed ID: 28780657
[TBL] [Abstract][Full Text] [Related]
8. Comparative Effectiveness of Rituximab and Common Induction Therapies for Lupus Nephritis: A Systematic Review and Network Meta-Analysis.
Li K; Yu Y; Gao Y; Zhao F; Liang Z; Gao J
Front Immunol; 2022; 13():859380. PubMed ID: 35444666
[TBL] [Abstract][Full Text] [Related]
9. Cyclophosphamide Versus Mycophenolate Versus Rituximab in Lupus Nephritis Remission Induction: A Historical Head-to-Head Comparative Study.
Goswami RP; Sircar G; Sit H; Ghosh A; Ghosh P
J Clin Rheumatol; 2019 Jan; 25(1):28-35. PubMed ID: 29561474
[TBL] [Abstract][Full Text] [Related]
10. Rituximab in the treatment of resistant lupus nephritis: therapy failure in rapidly progressive crescentic lupus nephritis.
Davies RJ; Sangle SR; Jordan NP; Aslam L; Lewis MJ; Wedgwood R; D'Cruz DP
Lupus; 2013 May; 22(6):574-82. PubMed ID: 23632989
[TBL] [Abstract][Full Text] [Related]
11. Outcome and predictors of renal survival in patients with lupus nephritis: Comparison between cyclophosphamide and mycophenolate mofetil.
Joo YB; Kang YM; Kim HA; Suh CH; Kim TJ; Park YW; Lee J; Lee JH; Yoo DH; Bae SC; Lee HS; Bang SY
Int J Rheum Dis; 2018 May; 21(5):1031-1039. PubMed ID: 29611341
[TBL] [Abstract][Full Text] [Related]
12. Multitarget therapy of mycophenolate mofetil and cyclosporine A for induction treatment of refractory lupus nephritis.
Jesus D; Rodrigues M; da Silva JAP; Inês L
Lupus; 2018 Jul; 27(8):1358-1362. PubMed ID: 29448882
[TBL] [Abstract][Full Text] [Related]
13. Low dose mycophenolate mofetil versus cyclophosphamide in the induction therapy of lupus nephritis in Nepalese population: a randomized control trial.
Sedhain A; Hada R; Agrawal RK; Bhattarai GR; Baral A
BMC Nephrol; 2018 Jul; 19(1):175. PubMed ID: 29996800
[TBL] [Abstract][Full Text] [Related]
14. Comparative efficacy and safety of mycophenolate mofetil and cyclophosphamide in the induction treatment of lupus nephritis: A systematic review and meta-analysis.
Jiang YP; Zhao XX; Chen RR; Xu ZH; Wen CP; Yu J
Medicine (Baltimore); 2020 Sep; 99(38):e22328. PubMed ID: 32957400
[TBL] [Abstract][Full Text] [Related]
15. Mizoribine versus mycophenolate mofetil or intravenous cyclophosphamide for induction treatment of active lupus nephritis.
Feng X; Gu F; Chen W; Liu Y; Wei H; Liu L; Yin S; Da Z; Sun L
Chin Med J (Engl); 2014; 127(21):3718-23. PubMed ID: 25382325
[TBL] [Abstract][Full Text] [Related]
16. A Comparison Of Mycophenolate Mofetil And Cyclophosphamide As Lupus Nephritis Induction Therapy.
Gul H; Mushtaq MS; Salim B; Samreen S; Nasim A; Khan M
J Ayub Med Coll Abbottabad; 2020; 32(4):454-458. PubMed ID: 33225643
[TBL] [Abstract][Full Text] [Related]
17. Mycophenolate mofetil in induction and maintenance therapy of severe lupus nephritis: a meta-analysis of randomized controlled trials.
Zhu B; Chen N; Lin Y; Ren H; Zhang W; Wang W; Pan X; Yu H
Nephrol Dial Transplant; 2007 Jul; 22(7):1933-42. PubMed ID: 17405792
[TBL] [Abstract][Full Text] [Related]
18. Rituximab as add-on therapy in patients with resistant lupus nephritis who have failed induction or maintenance therapy with other agents: A real-world experience from a single center in Mumbai.
Yadav S; Balakrishnan C; Mangat G; Kothari J
Lupus; 2024 Jan; 33(1):88-95. PubMed ID: 38048588
[TBL] [Abstract][Full Text] [Related]
19. Induction therapy for pediatric onset class IV lupus nephritis: Mycophenolate Mofetil versus Cyclophosphamide.
Chbihi M; Eveillard LA; Riller Q; Brousse R; Berthaud R; Quartier P; Salomon R; Charbit M; Avramescu M; Biebuyck N; Dehoux L; Garcelon N; Duong-Van-Huyen JP; Bader-Meunier B; Boyer O
J Nephrol; 2023 Apr; 36(3):829-839. PubMed ID: 36208405
[TBL] [Abstract][Full Text] [Related]
20. Comparison of low-dose intravenous cyclophosphamide with oral mycophenolate mofetil in the treatment of lupus nephritis.
Rathi M; Goyal A; Jaryal A; Sharma A; Gupta PK; Ramachandran R; Kumar V; Kohli HS; Sakhuja V; Jha V; Gupta KL
Kidney Int; 2016 Jan; 89(1):235-42. PubMed ID: 26489028
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
